Business Context and Reporting Period
This Form 8-K Current Report was filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on September 9, 2024, with the earliest event reported on that date. The filing discloses a strategic partnership and potential asset acquisition.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a proposed transaction structure.
- Proposed Consideration: Issuance of $250,000 worth of junior convertible preferred stock.
- Target Investment: The transaction is conditioned on securing a minimum of $500,000 in strategic investment, with a target of up to $3 million.
- Royalties: Single-digit royalties on net sales are contemplated.
Material Changes and Transaction Details
On September 9, 2024, the Company entered into a binding Letter of Intent with DataVault Holdings, Inc. (DVHI) regarding the licensing of clinical trial software and associated intellectual property.
- License Terms: Worldwide exclusive license with the right to grant sublicenses.
- Acquisition Option: The Company has a right of first refusal to fully acquire the assets.
- Stock Pricing: Preferred shares are priced at 180% of the five-day VWAP of common stock immediately preceding closing, multiplied by 1,000.
- Conversion Terms: Subject to shareholder approval, preferred stock converts to common stock at a 1:1,000 ratio. An anti-dilution adjustment applies if the stock price drops below the initial price at the six-month anniversary.
Guidance, Risks, and Contingencies
The transaction is subject to significant contingencies and is not yet finalized.
- Conditions Precedent: Completion of customary due diligence, negotiation of definitive agreements, and receipt of the Strategic Investment ($500,000 minimum).
- Approvals Required: Shareholder approval for the preferred stock issuance and conversion, as well as necessary third-party and regulatory approvals.
- Risk Warning: The filing explicitly states there can be no assurance that the Proposed Transaction will be completed on the terms contemplated or at all.
Investor Verification Checklist
- Verify the execution of definitive agreements following the Letter of Intent.
- Confirm the receipt of the minimum $500,000 strategic investment required to proceed.
- Monitor shareholder vote results regarding the issuance and conversion of junior convertible preferred stock.
- Review the final terms of the royalty structure and the specific definition of "net sales" in the definitive agreement.
- Check for any updates on the status of the $3 million investment target.